China's Fosun to buy out remaining shares of Henlius Biotech
(Reuters) -- Chinese conglomerate Fosun International will buy the remaining stake in Shanghai Henlius Biotech it does not already own in a deal that values the Hong Kong-listed drugmaker at $13.37 billion Hong Kong dollars ($1.71 billion), the companies said on Monday.